Apomorphine (Apokyn) vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: Dopamine receptor (non-ergoline agonist) · full Parkinson's Disease pipeline
Apomorphine (Apokyn)
Marketed by Supernus Pharmaceuticals and partners
NCT00142545 · Phase 3 · completed
The study was non-randomized, open-label, and had no comparator arm; all 800 participants received apomorphine. Its primary outcomes focused on safety monitoring, and no primary endpoint results were posted, so there is no controlled comparison showing benefit.
No aligned efficacy figure on record for this race.
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Apomorphine (Apokyn) | SER-252 (PEOZ-apomorphine) |
|---|---|---|
| OFF time, change | —Not posted · NCT00200525 | —Not reported |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00200525 | —Not reported |
| UPDRS Part III, change | —Not posted · NCT00200525 | —Not reported |
| MDS-UPDRS Part II, change | —Not posted · NCT00200525 | —Not reported |
OFF time, change
- Apomorphine (Apokyn)
- —Not posted · NCT00200525
- SER-252 (PEOZ-apomorphine)
- —Not reported
ON time without troublesome dyskinesia, change
- Apomorphine (Apokyn)
- —Not posted · NCT00200525
- SER-252 (PEOZ-apomorphine)
- —Not reported
UPDRS Part III, change
- Apomorphine (Apokyn)
- —Not posted · NCT00200525
- SER-252 (PEOZ-apomorphine)
- —Not reported
MDS-UPDRS Part II, change
- Apomorphine (Apokyn)
- —Not posted · NCT00200525
- SER-252 (PEOZ-apomorphine)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SER-252 (PEOZ-apomorphine): no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Apomorphine (Apokyn): 4 of 4 rows · SER-252 (PEOZ-apomorphine): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Apomorphine (Apokyn) |
|---|---|
| Dropout rate | 20.5%a NCT01770145 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 15.7%a NCT01770145 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 0%a NCT01770145 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | a nausea 19.7% yawning 7.9% somnolence 5.5% NCT01770145 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Apomorphine (Apokyn)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Apokyn)'s landscape · SER-252 (PEOZ-apomorphine)'s landscape